spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Prolaris 

 HSMN NewsFeed - 13 Feb 2020
Decipher GRID Signature Predicts Benefit from Chemotherapy in Men Diagnosed with Metastatic Prostate Cancer
Diagnostics Oncology
 HSMN NewsFeed - 29 Jan 2019
Nanospectra Biosciences Names Michael Brawer, M.D. as Chief Medical Officer
Devices Oncology Urology Personnel
 HSMN NewsFeed - 15 Sep 2017
Myriad Genetics Announces Positive Data Supporting New riskScore(TM) Test at the 36th Annual Conference of the National Society of Genetic Counselors
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 7 Sep 2017
Hereditary Cancer Risk Assessment Is an Important Option for Prostate Cancer Patients during Prostate Cancer Awareness Month
Diagnostics Oncology
 HSMN NewsFeed - 18 Aug 2017
EndoPredict(R) Receives Positive Coverage Decisions From Medicare and Anthem
Diagnostics Oncology Reimbursement
 HSMN NewsFeed - 25 May 2017
Medicare Coverage of Prolaris(R) Test Expands with the Addition of Men Diagnosed with Favorable Intermediate Risk Prostate Cancer
Diagnostics Oncology Reimbursement
 HSMN NewsFeed - 13 Mar 2017
Myriad Genetics Launches the EndoPredict(R) Test in the United States for Patients with Breast Cancer
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 7 Nov 2016
Myriad Will Seek Japanese Regulatory Approval for BRACAnalysis CDx(R)
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 4 Nov 2016
The GeneSight(R) Precision Medicine Test Drives Significant Medication Cost Savings in Patients with Generalized Anxiety Disorder
Diagnostics Personalized Medicine
 HSMN NewsFeed - 27 Oct 2016
The Myriad myPath(R) Melanoma Test Effectively Diagnosed Patients in the Largest Outcomes-Based Study for a Melanoma Diagnostic
Diagnostics Dermatology Oncology
 HSMN NewsFeed - 29 Sep 2016
Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy
Diagnostics Personnel
 HSMN NewsFeed - 18 Mar 2016
The Myriad myRisk(R) Hereditary Cancer Test Identifies 60 Percent More Deleterious Mutations in Patients with Endometrial Cancer
Diagnostics Oncology Personalized Medicine
 HSMN NewsFeed - 29 May 2015
Myriad Presents New myRisk(TM) Hereditary Cancer Data at 2015 ASCO Annual Meeting
Diagnostics Oncology
 HSMN NewsFeed - 8 Jan 2015
Myriad Obtains CE Mark for Tumor BRACAnalysis CDx(TM) and Launches Test in Europe as Companion Diagnostic for PARP Inhibitors
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 2 Dec 2014
Study Shows Prolaris(R) Could Save Healthcare System $6 Billion Over 10 Years
Diagnostics Urology Oncology
 HSMN NewsFeed - 19 Nov 2014
Crescendo Bioscience Highlights New Clinical Data on Vectra(R) DA at ACR
Diagnostics
 HSMN NewsFeed - 7 Nov 2014
Myriad myPath(TM) Melanoma Improves Diagnosis and Treatment Plans
Diagnostics Dermatology Oncology
 HSMN NewsFeed - 24 Oct 2014
Myriad Establishes Tumor BRACAnalysis CDx(TM) Laboratory in Europe
Diagnostics Oncology
 HSMN NewsFeed - 9 Sep 2014
Myriad myPath(TM) Melanoma Test Reduced Indeterminate Cases by 76 Percent and Changed Treatment in 35 Percent of Cases
Diagnostics Oncology
 HSMN NewsFeed - 2 Jun 2014
Myriad myPath(TM) Melanoma Test Improves the Reliability of Melanoma Diagnosis
Diagnostics Dermatology Oncology
 HSMN NewsFeed - 2 Jun 2014
Myriad Presents Clinical Data on Myriad myRisk(TM) Hereditary Cancer Test at ASCO
Diagnostics Oncology
 HSMN NewsFeed - 1 May 2014
Myriad to Launch EndoPredict(R) in Canada
Diagnostics Oncology Personalized Medicine
 HSMN NewsFeed - 3 Mar 2014
Myriad Publishes Clinical Utility Study for Prolaris(R)
Diagnostics Urology
 HSMN NewsFeed - 29 Jan 2014
Myriad's Prolaris(R) Test Significantly Modifies Treatment Decisions for Patients With Prostate Cancer
Diagnostics Oncology
 HSMN NewsFeed - 4 Dec 2013
Myriad's Prolaris(R) Test Guides Treatment Decisions for Men with Prostate Cancer
Diagnostics Urology Oncology
 HSMN NewsFeed - 13 Jun 2013
Supreme Court Upholds Myriad's cDNA Patent Claims
Diagnostics Oncology Litigation
 HSMN NewsFeed - 5 Mar 2013
Myriad's Prolaris(R) Test Predicts Risk of Prostate Cancer Recurrence in Fourth Peer Reviewed Study
Diagnostics Urology Oncology
 HSMN NewsFeed - 9 Dec 2011
Myriad Genetics Presents BRACAnalysis(R) Cost-Effectiveness Study at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Diagnostics Oncology
 HSMN NewsFeed - 20 Dec 2010
Myriad Genetics Launches PANEXIA, New Predictive Test for Hereditary Pancreatic and Related Cancers
Diagnostics Oncology
 HSMN NewsFeed - 8 Dec 2010
Myriad Acquires Novel Technology From Melanoma Diagnostics
Diagnostics Oncology Acquisitions
 HSMN NewsFeed - 26 Oct 2010
Myriad and Abbott Enter Into Cooperative Agreement
Diagnostics Oncology
 HSMN NewsFeed - 2 Mar 2010
Myriad Genetics Launches PROLARIS(TM): First Diagnostic Test to Predict Prostate Cancer Recurrence
Diagnostics Oncology
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.